TABLE 1.
Characteristics of serum panels used in this study
| Serum testing panel |
RT-PCR | FRµNT90 | Country | Yr | ||
|---|---|---|---|---|---|---|
| Virus | No. of specimens | Single or paireda | ||||
| ZIKV | 42 | Paired | + | 4-fold increase | Puerto Rico | 2016 |
| DENV | 54 | Paired | + | 4-fold increase | Brazil | 2009 |
| WNV | 97 | Single | NDc | Highest titer | United States (South Dakota) | 2008 |
| Otherb | 76 | Single | ||||
a
Paired specimens, including acute specimens, were collected within 7 days of disease onset, and convalescent-phase specimens were collected within 7 to 30 days after onset of symptoms.
b
A control serum panel consists of 30 non-DENV patient serum specimens, including IgG-positive yellow fever-17D (YF-17D) postvaccination sera (n = 10), acute-phase serum specimens from St. Louis encephalitis virus (SLEV; n = 2), chikungunya virus (n = 10), or other nonarboviral (n = 8) infections, and 46 normal human sera from the CDC blood bank.
c
ND, not determined due to undetectable viremia.